Rifampin in association with isoniazid, streptomycin, and ethambutol, respectively, in the initial treatment of pulmonary tuberculosis.
V Nitti, E Catena, Federica Veneri, G. De Michele, Andrea Marra
Abstract
V Nitti, E Catena, Federica Veneri, G. De Michele, Andrea Marra
Abstract
A clinical trial of rifampin in association with isoniazid, streptomycin, or ethambutol was carried out in 220 patients with tuberculosis who had never received antituberculous drugs. A control group of patients was treated with isoniazid and streptomycin. The efficacy of rifampin was comparable to that of isoniazid; the combination of rifampin and isoniazid gave better results than isoniazid with streptomycin. Rifampin was well tolerated and no side effects were noted.
OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
A clinical trial of rifampin in association with isoniazid, streptomycin, or ethambutol was carried out in 220 patients with tuberculosis who had never received antituberculous drugs. A control group of patients was treated with isoniazid and streptomycin. The efficacy of rifampin was comparable to that of isoniazid; the combination of rifampin and isoniazid gave better results than isoniazid with streptomycin. Rifampin was well tolerated and no side effects were noted.
Key concepts: Isoniazid, Ethambutol, Streptomycin, Medicine, Tuberculosis, Rifampicin, Pulmonary tuberculosis, Antibiotics